Identification of novel tumor antigens and immune subtypes in breast cancer patients for mRNA vaccine development

Author:

Yu Haiyan1,Liu Junping2,Li Lintai3,He Jingquan4,Li Dandan4,Hou Xianliang4,Cai Wanxia4,Chen Yumei4,Dai Yong4,Tang Donge4,Tang Min5,Zhang Wei1

Affiliation:

1. Southern Medical University

2. The West China Hospital, The West China Tianfu Hospital Sichuan University,Sichuan

3. South China Hospital, Shenzhen University

4. The Second Clinical Medical College of Jinan University

5. Chongqing Medical University

Abstract

Abstract Background:Breast cancer has overtaken lung cancer as the world's most common malignancy. Despite the development of some mRNA vaccines, no satisfactory vaccination for breast cancer has entered clinical application. Methods:In this study, we used multiple analyses of expression datasets from public sources to find new possible tumor antigens for breast cancer and to hunt for potential treatment-sensitive patients. Results: We identified the antigens DST, ANO6, LAMA3, and NEDD9 as putative candidates. Furthermore, we found five predictive genes to identify specific patients inclined for vaccination, namely TRBC2, CD3D, CD27, CD3E, and TRBV28. Following that, we discovered three immunological subtypes of breast cancer, Cluster 1 and Cluster 3, which were recognized as "cold tumors" with minimal immune activity and were more likely to respond to vaccination. We uncovered that Cluster 1 and Cluster 3 could be further separated into two subgroups, each with distinct immune cell infiltration patterns, suggesting that vaccine responses could differ among these patients. The findings of our study lay theoretical foundation for the development of mRNA vaccine and provide new opportunities for personalized treatment.

Publisher

Research Square Platform LLC

Reference45 articles.

1. Latest global cancer data: Cancer burden rises to 19.3 million new cases and 10.0 million cancer deaths in 2020 [https://www.iarc.who.int/fr/news-events/latest-global-cancer-data-cancer-burden-rises-to-19-3-million-new-cases-and-10-0-million-cancer-deaths-in-2020/]

2. Cancer Stat Facts: Female Breast Cancer [https://seer.cancer.gov/statfacts/]

3. Adjuvant and neoadjuvant breast cancer treatments: A systematic review of their effects on mortality;Kerr AJ;Cancer Treat Rev,2022

4. Knoedler S, Kauke-Navarro M, Knoedler L, Friedrich S, Matar DY, Diatta F, Mookerjee VG, Ayyala H, Wu M, Kim BS et al: Racial Disparities in Surgical Outcomes after Mastectomy in 223,000 Female Breast Cancer Patients - A Retrospective Cohort Study. Int j surg 2023, null(null):null.

5. Dolgin E: 'Remarkable' AI tool designs mRNA vaccines that are more potent and stable. Nature 2023, null(618):E18.

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3